| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192466 | Journal of Thoracic Oncology | 2016 | 21 Pages |
Abstract
Unfit patients with ultracentral tumors who were treated using this scheme had a high local control and a median survival of 15.9 months. Despite manifestation of rates of a fatal lung bleeding comparable to those seen with conventional radiotherapy for endobronchial tumors, the overall rate of G5 toxicity is of potential concern. Additional work is needed to identify tumor and treatment factors related to hemorrhage.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hilâl MD, Niels MD, PhD, Max MbChB., PhD, FRCP, FRCR, Patricia MD, Wilko PhD, Eva MD, Sayed MD, Esther MD, Femke MD, PhD, Adrianus J. MD, PhD, Ben MD, PhD, Suresh FRCR, PhD,